UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow JonesJul 1 19:05

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $60 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $60 price target.

BenzingaJul 1 18:55

UroGen Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/01/2024 257.57% HC Wainwright & Co. $60 → $60 Reiterates Buy → Buy 06/14/2024 218.83% Ladenburg Thalman

BenzingaJul 1 18:53

H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $60

H.C. Wainwright analyst Ram Selvaraju maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and maintains the target price at $60.According to TipRanks data, the analyst has a success rate of 36.9

Futu NewsJul 1 18:31 · Ratings

TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $102

TD Cowen analyst Tara Bancroft maintains $UroGen Pharma Ltd(URGN.US)$ with a buy rating, and sets the target price at $102.According to TipRanks data, the analyst has a success rate of 50.0% and a tot

Futu NewsJun 21 18:33 · Ratings

Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Maintains Target Price $22

Goldman Sachs analyst Paul Choi maintains $UroGen Pharma Ltd(URGN.US)$ with a hold rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 0.0% and

Futu NewsJun 19 02:32 · Ratings